Checchi Capital Advisers LLC Has $1.56 Million Holdings in Stryker Corporation $SYK

Checchi Capital Advisers LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 3.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,934 shares of the medical technology company’s stock after selling 132 shares during the period. Checchi Capital Advisers LLC’s holdings in Stryker were worth $1,556,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Penobscot Investment Management Company Inc. grew its position in shares of Stryker by 0.9% during the 2nd quarter. Penobscot Investment Management Company Inc. now owns 42,391 shares of the medical technology company’s stock worth $16,771,000 after purchasing an additional 390 shares in the last quarter. AMF Tjanstepension AB grew its position in shares of Stryker by 319.9% during the 2nd quarter. AMF Tjanstepension AB now owns 193,817 shares of the medical technology company’s stock worth $76,697,000 after purchasing an additional 147,663 shares in the last quarter. LGT Fund Management Co Ltd. grew its position in shares of Stryker by 23.5% during the 2nd quarter. LGT Fund Management Co Ltd. now owns 4,901 shares of the medical technology company’s stock worth $1,939,000 after purchasing an additional 934 shares in the last quarter. Tilia Fiduciary Partners Inc. grew its position in shares of Stryker by 1.1% during the 2nd quarter. Tilia Fiduciary Partners Inc. now owns 7,266 shares of the medical technology company’s stock worth $2,875,000 after purchasing an additional 78 shares in the last quarter. Finally, Cape ANN Savings Bank grew its position in shares of Stryker by 6.7% during the 2nd quarter. Cape ANN Savings Bank now owns 2,611 shares of the medical technology company’s stock worth $1,033,000 after purchasing an additional 165 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Rothschild & Co Redburn assumed coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock. Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Redburn Partners set a $420.00 price target on shares of Stryker in a report on Thursday, September 18th. Finally, BTIG Research reissued a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $430.33.

Stryker Trading Up 1.1%

SYK opened at $370.59 on Friday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average of $382.81 and a 200-day moving average of $378.93. The stock has a market cap of $141.68 billion, a PE ratio of 49.08, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.